Formosa Pharmaceuticals Investors
Corporate Governance
Board of Directors
Major Policies
- Article of incorporation
- Corporate governance structure
- Management of assets
- Management of related party transactions
- Management of the prevention of insider trading
- Procedures and methods for acquiring or disposing of assets
- Ethical corporate management best practice principles acquiring or disposing of assets
- Code of ethics
- Procedures for election of directors
- Operational procedures for endorsements and guarantees
- Corporate governance best practice principles
- Corporate sustainable development best practice principles
- Operational procedures for loaning funds to others
- Rules of procedure for shareholders meetings
Major Resolutions
News Highlight
Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
2025-06-09
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North
